Beauty Health Co (SKIN) reported Q2 2025 earnings that exceeded market expectations, with revenue of $78.2 million and EPS of $0.03, surpassing forecasts of $74.51 million and -$0.06. The stock surged 22.01% to $1.94 per share, driven by improved financial performance, debt restructuring, and guidance upgrades. The company highlighted strong gross margins, recurring revenue growth, and upcoming product launches.

Beauty Health, the parent company of the Hydrafacial brand, saw its stock surge 20.75% to $1.92 after-hours following strong second-quarter financial results, including $78.2 million in revenue and $19.7 million in net income, with a raised full-year guidance for 2025.

Revvity (RVTY) reported Q2 earnings of $1.18 per share, exceeding the Zacks Consensus Estimate of $1.14, and revenue of $720.28 million, surpassing the estimate by 1.27%. The company, part of the Zacks Medical Services industry, has outperformed earnings estimates four times in the last four quarters. Its Zacks Rank is #3 (Hold), with current consensus EPS estimates of $1.27 for the next quarter and $4.82 for the fiscal year. A competitor, The Beauty Health Company (SKIN), is expected to report a quarterly loss of $0.06 per share.

The Beauty Health Company (NASDAQ:SKIN), home to flagship brand Hydrafacial™, announced the launch of the Hydrafacial HydraFillic with Pep9™ Booster, a new skin booster formulated with nine peptides to address signs of aging. Clinical testing and consumer surveys highlight its efficacy in improving skin firmness, hydration, and appearance of fine lines and wrinkles.

BeautyHealth, a company behind the Hydrafacial™ treatment, achieved a milestone with 35,000 devices installed globally, reinforcing its leadership in the hydradermabrasion market. The treatment, which combines seven skin therapies, has driven 5 million treatments last year and maintains a 96% 'Worth It' rating on RealSelf. CEO Marla Beck highlighted the treatment's role in practice growth and its 1.5 treatments-per-second global demand.